{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:30:48Z","timestamp":1771597848799,"version":"3.50.1"},"reference-count":91,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Alzheimer and Parkinson diseases are associated with cholinergic neuron loss and deterioration\nof bone mineral density. Gene therapy through either gene transfer, CRISPR gene editing, or\nCRISPR gene modulation holds the potential to cure Alzheimer and Parkinson diseases. The emerging\nrole of weight-bearing exercise in the prevention of, and care for, osteoporosis, obesity, and diabetes\nhas been previously recognized. Moreover, endurance exercise offers a viable alternative to reduce\namyloid peptides deposits while increasing bone mineral density in Alzheimer and Parkinson patients.\n\u03b2-amyloid peptides, \u03b1-synuclein, and tau aggregates start building up two decades before the onset of\nAlzheimer and Parkinson diseases. Therefore, an early intervention program for the detection of these\ndeposits is required to prevent or delay the onset of these diseases. This article spots light on the potential\nof gene therapy for Alzheimer and Parkinson diseases.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523223666230419101023","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T06:34:05Z","timestamp":1683095645000},"page":"163-169","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Gene Therapy for Alzheimer and Parkinson Diseases"],"prefix":"10.2174","volume":"23","author":[{"given":"Jasen F.","family":"Saad","sequence":"first","affiliation":[{"name":"Department of Gene Therapy, Saad Pharmaceuticals, Juhkentali 8, Tallinn 10132, Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3170-3449","authenticated-orcid":true,"given":"Fawzy A.","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic\nSurgery, Harvard Medical School, 300 Longwood Avenue, Boston, MA 20115, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.2174\/138161211798072472","volume":"17","author":"Jorge N.R.","year":"2011","unstructured":"Jorge N.R.; Pereira de AL. Gene therapy for Parkinson\u2019s and Alzheimer\u2019s diseases: From the bench to clinical trials. Curr Pharm Des 2011,17(31),3434-3445","journal-title":"Curr Pharm Des"},{"key":"ref=2","first-page":"2021","volume":"147264","author":"Owens L.V.","year":"1753","unstructured":"Owens L.V.; Benedetto A.; Dawson N.; Gaffney C.J.; Parkin E.T.; Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer\u2019s disease. Brain Res 1753,147264,2021","journal-title":"Brain Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/13543784.14.7.913","volume":"14","author":"Braddock M.","year":"2005","unstructured":"Braddock M.; Safely slowing down the decline in Alzheimer\u2019s disease: Gene therapy shows potential. Expert Opin Investig Drugs 2005,14(7),913-915","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e3181f6128c","volume":"75","author":"Chung K.A.","year":"2010","unstructured":"Chung K.A.; Lobb B.M.; Nutt J.G.; Horak F.B.; Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010,75(14),1263-1269","journal-title":"Neurology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bone.2012.09.013","volume":"52","author":"Zhao Y.","year":"2013","unstructured":"Zhao Y.; Shen L.; Ji H.F.; Osteoporosis risk and bone mineral density levels in patients with Parkinson\u2019s disease: A meta-analysis. Bone 2013,52(1),498-505","journal-title":"Bone"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5606\/tftrd.2020.3803","volume":"66","year":"2020","unstructured":"Ba\u015fg\u00f6z BB, \u0130nce S, Safer U, Naharc\u0131 M\u0130, Ta\u015f\u00e7\u0131 \u0130. Low bone density and osteoporosis among older adults with Alzheimer\u2019s disease, vascular dementia, and mixed dementia: A cross-sectional study with prospective enrollment. Turk J Phys Med Rehabil 2020,66(2),193-200","journal-title":"Turk J Phys Med Rehabil"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.18632\/aging.101982","volume":"11","author":"Whittemore K.","year":"2019","unstructured":"Whittemore K.; Derevyanko A.; Martinez P.; Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice. Aging 2019,11(10),2916-2948","journal-title":"Aging"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"180036","DOI":"10.1038\/sdata.2018.36","volume":"5","author":"Ping L.","year":"2018","unstructured":"Ping L.; Duong D.M.; Yin L.; Global quantitative analysis of the human brain proteome in Alzheimer\u2019s and Parkinson\u2019s Disease. Sci Data 2018,5(1),180036","journal-title":"Sci Data"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"648740","DOI":"10.1155\/2014\/648740","volume":"2014","author":"Xie A.","year":"2014","unstructured":"Xie A.; Gao J.; Xu L.; Meng D.; Shared mechanisms of neurodegeneration in Alzheimer\u2019s disease and Parkinson\u2019s disease. BioMed Res Int 2014,2014,648740","journal-title":"BioMed Res Int"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13041-019-0436-5","volume":"12","author":"Kelly J.","year":"2019","unstructured":"Kelly J.; Moyeed R.; Carroll C.; Albani D.; Li X.; Gene expression meta-analysis of Parkinson\u2019s disease and its relationship with Alzheimer\u2019s disease. Mol Brain 2019,12(1),16","journal-title":"Mol Brain"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"5221","DOI":"10.18632\/aging.102943","volume":"12","author":"Kelly J.","year":"2020","unstructured":"Kelly J.; Moyeed R.; Carroll C.; Luo S.; Li X.; Genetic networks in Parkinson\u2019s and Alzheimer\u2019s disease. Aging 2020,12(6),5221-5243","journal-title":"Aging"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12031-016-0829-1","volume":"60","author":"Li X.","year":"2016","unstructured":"Li X.; James S.; Lei P.; Interactions between \u03b1-Synuclein and tau protein: Implications to neurodegenerative disorders. J Mol Neurosci 2016,60(3),298-304","journal-title":"J Mol Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2017.01.017","volume":"131","author":"Giacomelli C.","year":"2017","unstructured":"Giacomelli C.; Daniele S.; Martini C.; Potential biomarkers and novel pharmacological targets in protein aggregation-related neurodegenerative diseases. Biochem Pharmacol 2017,131,1-15","journal-title":"Biochem Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/cts.12612","volume":"12","author":"Irion S.","year":"2019","unstructured":"Irion S.; Cell Therapies for Parkinson\u2019s Disease. Clin Transl Sci 2019,12(2),95-97","journal-title":"Clin Transl Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","volume":"14","author":"Twohig D","year":"2019","unstructured":"Twohig D; Nielsen HM; \u03b1-synuclein in the pathophysiology of Alzheimer\u2019s disease. Mol Neurodegener 2019,14(1),23","journal-title":"Mol Neurodegener"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1212\/WNL.0000000000004756","volume":"89","author":"Dodel R.","year":"2017","unstructured":"Dodel R.; Comment: \u03b2-Amyloid pathology and Parkinson disease. Neurology 2017,89(23),2339","journal-title":"Neurology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"Masliah E","year":"2001","unstructured":"Masliah E; Rockenstein E; Veinbergs I; \u03b2-Amyloid peptides enhance \u03b1-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc Natl Acad Sci 2001,98(21),12245-12250","journal-title":"Proc Natl Acad Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.neuron.2022.03.034","volume":"110","author":"Lee W.J.","year":"2022","unstructured":"Lee W.J.; Brown J.A.; Kim H.R.; Regional A\u03b2-tau interactions promote onset and acceleration of Alzheimer\u2019s disease tau spreading. Neuron 2022,110(12),1932-1943.e5","journal-title":"Neuron"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnmol.2018.00053","volume":"11","author":"Daniele S","year":"2018","unstructured":"Daniele S; Frosini D; Pietrobono D; \u03b1-Synuclein heterocomplexes with \u03b2-amyloid are increased in red blood cells of parkinson\u2019s disease patients and correlate with disease severity. Front Mol Neurosci 2018,11,53","journal-title":"Front Mol Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/nyas.14231","volume":"1462","author":"Saad F.A.","year":"2020","unstructured":"Saad F.A.; Novel insights into the complex architecture of osteoporosis molecular genetics. Ann N Y Acad Sci 2020,1462(1),37-52","journal-title":"Ann N Y Acad Sci"},{"key":"ref=21","first-page":"15","volume":"51","author":"Shimizu M.E.","year":"2002","unstructured":"Shimizu M.E.; Ishizaki F.; Nakamura S.; Results of a home exercise program for patients with osteoporosis resulting from neurological disorders. Hiroshima J Med Sci 2002,51(1),15-22","journal-title":"Hiroshima J Med Sci"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2174\/156720501108140910122849","volume":"11","author":"Nascimento C.","year":"2014","unstructured":"Nascimento C.; Pereira J.; Andrade L.; Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res 2014,11(8),799-805","journal-title":"Curr Alzheimer Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/brainsci11010063","volume":"11","author":"Puente-Gonz\u00e1lez A.S.","year":"2021","unstructured":"Puente-Gonz\u00e1lez A.S.; S\u00e1nchez-S\u00e1nchez M.C.; Fern\u00e1ndez-Rodr\u00edguez E.J.; Hern\u00e1ndez-Xumet J.E.; Barbero-Iglesias F.J.; M\u00e9ndez-S\u00e1nchez R.; Effects of 6-month multimodal physical exercise program on bone mineral density, fall risk, balance, and gait in patients with alzheimer\u2019s disease: A controlled clinical trial. Brain Sci 2021,11(1),63","journal-title":"Brain Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"45008","DOI":"10.18632\/oncotarget.16726","volume":"8","author":"Arsenis N.C.","year":"2017","unstructured":"Arsenis N.C.; You T.; Ogawa E.F.; Tinsley G.M.; Zuo L.; Physical activity and telomere length: Impact of aging and potential mechanisms of action. Oncotarget 2017,8(27),45008-45019","journal-title":"Oncotarget"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"652497","DOI":"10.3389\/fgene.2021.652497","volume":"12","author":"Sellami M.","year":"2021","unstructured":"Sellami M.; Bragazzi N.; Prince M.S.; Denham J.; Elrayess M.; Regular, intense exercise training as a healthy aging lifestyle strategy: Preventing DNA damage, telomere shortening and adverse DNA methylation changes over a lifetime. Front Genet 2021,12,652497","journal-title":"Front Genet"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/cells11010153","volume":"11","author":"Haupt S.","year":"2022","unstructured":"Haupt S.; Niedrist T.; Sourij H.; Schwarzinger S.; Moser O.; The impact of exercise on telomere length, dna methylation and metabolic footprints. Cells 2022,11(1),153","journal-title":"Cells"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/00913847.1991.11710211","volume":"19","author":"Poser C.M.","year":"1991","unstructured":"Poser C.M.; Ronthal M.; Exercise and Alzheimer\u2019s disease, Parkinson\u2019s disease, and multiple sclerosis. Phys Sportsmed 1991,19(12),85-92","journal-title":"Phys Sportsmed"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3233\/JAD-161032","volume":"56","author":"Wang Q.","year":"2017","unstructured":"Wang Q.; Li W.X.; Dai S.X.; Meta-Analysis of parkinson\u2019s disease and Alzheimer\u2019s disease revealed commonly impaired pathways and dysregulation of NRF2-dependent genes. J Alzheimers Dis 2017,56(4),1525-1539","journal-title":"J Alzheimers Dis"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"112488","DOI":"10.1016\/j.bbr.2020.112488","volume":"6","author":"da Costa D.T.M.","year":"2020","unstructured":"da Costa D.T.M.; de Bruin P.F.C.; de Matos R.S.; de Bruin G.S.; Maia C.C.; Exercise effects on brain and behavior in healthy mice, Alzheimer\u2019s disease and Parkinson\u2019s disease model-A systematic review and meta-analysis. Behav Brain Res 2020,6(383),112488","journal-title":"Behav Brain Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fnins.2020.00157","volume":"14","author":"Song Y.","year":"2020","unstructured":"Song Y.; Li S.; Li X.; The effect of estrogen replacement therapy on Alzheimer\u2019s disease and parkinson\u2019s disease in postmenopausal women: A meta-analysis. Front Neurosci 2020,14,157","journal-title":"Front Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.3349\/ymj.2004.45.Suppl.28","volume":"45","author":"Blesch A.","year":"2004","unstructured":"Blesch A.; Tuszynski M.H.; Gene therapy and cell transplantation for Alzheimer\u2019s disease and spinal cord injury. Yonsei Med J 2004,45,S28","journal-title":"Yonsei Med J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jgeb.2018.09.002","volume":"16","author":"Fleifel D.","year":"2018","unstructured":"Fleifel D.; Rahmoon M.A.; AlOkda A.; Nasr M.; Elserafy M.; El-Khamisy S.F.; Recent advances in stem cells therapy: A focus on cancer, Parkinson\u2019s and Alzheimer\u2019s. J Genet Eng Biotechnol 2018,16(2),427-432","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-10-1","volume":"10","author":"Politis M.","year":"2012","unstructured":"Politis M.; Lindvall O.; Clinical application of stem cell therapy in Parkinson\u2019s disease. BMC Med 2012,10(1),1","journal-title":"BMC Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/sci-2021-063","volume":"9","author":"Karvelas N.","year":"2022","unstructured":"Karvelas N.; Bennett S.; Politis G.; Kouris N.I.; Kole C.; Advances in stem cell therapy in Alzheimer\u2019s disease: a comprehensive clinical trial review. Stem Cell Investig 2022,9,2","journal-title":"Stem Cell Investig"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/mds.27742","volume":"34","author":"Collier T.J.","year":"2019","unstructured":"Collier T.J.; Sortwell C.E.; Mercado N.M.; Steece-Collier K.; Cell therapy for Parkinson\u2019s disease: Why it doesn\u2019t work every time. Mov Disord 2019,34(8),1120-1127","journal-title":"Mov Disord"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2217\/bmm.09.92","volume":"4","author":"Ryan N.S.","year":"2010","unstructured":"Ryan N.S.; Rossor M.N.; Correlating familial Alzheimer\u2019s disease gene mutations with clinical phenotype. Biomarkers Med 2010,4(1),99-112","journal-title":"Biomarkers Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.3390\/ijms19103199","volume":"19","author":"Teijido O.","year":"2018","unstructured":"Teijido O.; Cacabelos R.; Pharmacoepigenomic interventions as novel potential treatments for alzheimer\u2019s and parkinson\u2019s diseases. Int J Mol Sci 2018,19(10),3199","journal-title":"Int J Mol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"402369","DOI":"10.1155\/2013\/402369","volume":"2013","author":"Aoki Y.","year":"2013","unstructured":"Aoki Y.; Yokota T.; Wood M.J.A.; Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. BioMed Res Int 2013,2013,402369","journal-title":"BioMed Res Int"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1046\/j.0022-3042.2002.00770.x","volume":"80","author":"Bodendorf U.","year":"2002","unstructured":"Bodendorf U.; Danner S.; Fischer F.; Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. J Neurochem 2002,80(5),799-806","journal-title":"J Neurochem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12035-013-8484-9","volume":"49","author":"Lee J.H.","year":"2014","unstructured":"Lee J.H.; Jiang Y.; Han D.H.; Shin S.K.; Choi W.H.; Lee M.J.; Targeting estrogen receptors for the treatment of Alzheimer\u2019s disease. Mol Neurobiol 2014,49(1),39-49","journal-title":"Mol Neurobiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"E164","DOI":"10.1152\/ajpendo.00008.2021","volume":"321","author":"Bagit A.","year":"2021","unstructured":"Bagit A.; Hayward G.C.; MacPherson R.E.K.; Exercise and estrogen: Common pathways in Alzheimer\u2019s disease pathology. Am J Physiol Endocrinol Metab 2021,321(1),E164-E168","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/85059","volume":"4","author":"Luo Y.","year":"2001","unstructured":"Luo Y.; Bolon B.; Kahn S.; Mice deficient in BACE1, the Alzheimer\u2019s \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation. Nat Neurosci 2001,4(3),231-232","journal-title":"Nat Neurosci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0896-6273(03)00810-9","volume":"41","author":"Ohno M.","year":"2004","unstructured":"Ohno M.; Sametsky E.A.; Younkin L.H.; BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer\u2019s disease. Neuron 2004,41(1),27-33","journal-title":"Neuron"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/humc.2017.231","volume":"29","author":"Rosenberg J.B.","year":"2018","unstructured":"Rosenberg J.B.; Kaplitt M.G.; De B.P.; AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease. Hum Gene Ther Clin Dev 2018,29(1),24-47","journal-title":"Hum Gene Ther Clin Dev"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.3390\/ijerph16214196","volume":"16","author":"Im J.Y.","year":"2019","unstructured":"Im J.Y.; Bang H.S.; Seo D.Y.; The effects of 12 weeks of a combined exercise program on physical function and hormonal status in elderly Korean women. Int J Environ Res Public Health 2019,16(21),4196","journal-title":"Int J Environ Res Public Health"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2337\/diacare.27.2.629","volume":"27","author":"Kriketos A.D.","year":"2004","unstructured":"Kriketos A.D.; Gan S.K.; Poynten A.M.; Furler S.M.; Chisholm D.J.; Campbell L.V.; Exercise increases adiponectin levels and insulin sensitivity in humans. Diabet Care 2004,27(2),629-630","journal-title":"Diabet Care"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF02873574","volume":"25","author":"Zhaosheng T.","year":"2005","unstructured":"Zhaosheng T.; Li Y.; Chengying G.; Yun L.; Lian Z.; Effect of exercise on the expression of adiponectin mRNA and GLUT4 mRNA in type 2 diabetic rats. J Huazhong Univ Sci Technolog Med Sci 2005,25(2),191-193, 201","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.archger.2009.07.001","volume":"51","author":"Aldred S.","year":"2010","unstructured":"Aldred S.; Mecocci P.; Decreased dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) concentrations in plasma of Alzheimer\u2019s disease (AD) patients. Arch Gerontol Geriatr 2010,51(1),e16-e18","journal-title":"Arch Gerontol Geriatr"},{"key":"ref=49","first-page":"27","volume":"8","author":"Ng R.C.L.","year":"2020","unstructured":"Ng R.C.L.; Jian M.; Yick L.W.; Adiponectin gene therapy for Alzheimer disease in a mouse model: Abridged secondary publication. Hong Kong Med J 2020,8(6),27-33","journal-title":"Hong Kong Med J"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ijbiomac.2022.03.203","volume":"208","author":"Arora S.","year":"2022","unstructured":"Arora S.; Kanekiyo T.; Singh J.; Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer\u2019s disease pathology in transgenic mouse model. Int J Biol Macromol 2022,208,901-911","journal-title":"Int J Biol Macromol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1093\/hmg\/ddaa179","volume":"29","author":"Griciuc A.","year":"2020","unstructured":"Griciuc A.; Federico A.N.; Natasan J.; Gene therapy for Alzheimer\u2019s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet 2020,29(17),2920-2935","journal-title":"Hum Mol Genet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/mt.2013.118","volume":"21","author":"Murphy S.R.","year":"2013","unstructured":"Murphy S.R.; Chang C.C.Y.; Dogbevia G.; Acat1 knockdown gene therapy decreases amyloid-\u03b2 in a mouse model of Alzheimer\u2019s disease. Mol Ther 2013,21(8),1497-1506","journal-title":"Mol Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/mt.2009.175","volume":"18","author":"Hudry E.","year":"2010","unstructured":"Hudry E.; Van Dam D.; Kulik W.; Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer\u2019s disease. Mol Ther 2010,18(1),44-53","journal-title":"Mol Ther"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s11064-007-9324-y","volume":"32","author":"Bonifati V.","year":"2007","unstructured":"Bonifati V.; LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson\u2019s disease. Neurochem Res 2007,32(10),1700-1708","journal-title":"Neurochem Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/humu.21277","volume":"31","author":"Nuytemans K.","year":"2010","unstructured":"Nuytemans K.; Theuns J.; Cruts M.; Van Broeckhoven C.; Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat 2010,31(7),763-780","journal-title":"Hum Mutat"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"489830","DOI":"10.1100\/2012\/489830","volume":"2012","author":"Copped\u00e8 F.","year":"2012","unstructured":"Copped\u00e8 F.; Genetics and epigenetics of Parkinson\u2019s disease. Scienti World J 2012,2012,489830","journal-title":"Scienti World J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.05.002","volume":"131","author":"Lardenoije R.","year":"2015","unstructured":"Lardenoije R.; Iatrou A.; Kenis G.; The epigenetics of aging and neurodegeneration. Prog Neurobiol 2015,131,21-64","journal-title":"Prog Neurobiol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s13311-011-0069-6","volume":"8","author":"Lindvall O.","year":"2011","unstructured":"Lindvall O.; Bj\u00f6rklund A.; Cell therapeutics in Parkinson\u2019s disease. Neurotherapeutics 2011,8(4),539-548","journal-title":"Neurotherapeutics"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"Freed C.R.","year":"2001","unstructured":"Freed C.R.; Greene P.E.; Breeze R.E.; Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N Engl J Med 2001,344(10),710-719","journal-title":"N Engl J Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"629-644, 642-644","DOI":"10.1227\/01.NEU.0000325491.89984.CE","volume":"63","author":"Richardson RM","year":"2008","unstructured":"Richardson RM; Larson PS; Bankiewicz KS;  Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models Neurosurgery 2008,63(4),629-644, 642-644","journal-title":"Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models Neurosurgery"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2ps2","DOI":"10.1126\/scitranslmed.3000350","volume":"1","author":"Bj\u00f6rklund A.","year":"2009","unstructured":"Bj\u00f6rklund A.; Bj\u00f6rklund T.; Kirik D.; Gene therapy for dopamine replacement in Parkinson\u2019s disease. Sci Transl Med 2009,1(2),2ps2","journal-title":"Sci Transl Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/mds.27993","volume":"35","author":"Nutt J.G.","year":"2020","unstructured":"Nutt J.G.; Curtze C.; Hiller A.; Aromatic L-Amino acid decarboxylase gene therapy enhances levodopa response in parkinson\u2019s disease. Mov Disord 2020,35(5),851-858","journal-title":"Mov Disord"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2ra4","DOI":"10.1126\/scitranslmed.3000130","volume":"1","author":"Jarraya B.","year":"2009","unstructured":"Jarraya B.; Boulet S.; Scott Ralph G.; Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 2009,1(2),2ra4","journal-title":"Sci Transl Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e14712","DOI":"10.15252\/emmm.202114712","volume":"13","author":"Hwu P.W.L.","year":"2021","unstructured":"Hwu P.W.L.; Kiening K.; Anselm I.; Gene therapy in the putamen for curing AADC deficiency and Parkinson\u2019s disease. EMBO Mol Med 2021,13(9),e14712","journal-title":"EMBO Mol Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","volume":"98","author":"Christine C.W.","year":"2022","unstructured":"Christine C.W.; Richardson R.M.; Van Laar A.D.; Safety of AADC gene therapy for moderately advanced parkinson disease. Neurology 2022,98(1),e40-e50","journal-title":"Neurology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.3233\/JPD-212739","volume":"11","author":"Abeliovich A.","year":"2021","unstructured":"Abeliovich A.; Hefti F.; Sevigny J.; Gene therapy for Parkinson\u2019s Disease associated with GBA1 Mutations. J Parkinsons Dis 2021,11(s2),S183-S188","journal-title":"J Parkinsons Dis"},{"key":"ref=67","first-page":"813","volume":"11","author":"Diaz-Nido J.","year":"2010","unstructured":"Diaz-Nido J.; NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson\u2019s disease. Curr Opin Investig Drugs 2010,11(7),813-822","journal-title":"Curr Opin Investig Drugs"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1111\/j.1471-4159.2006.04336.x","volume":"100","author":"Lin P.","year":"2007","unstructured":"Lin P.; Li F.; Zhang Y.W.; Calnuc binds to Alzheimer\u2019s beta-amyloid precursor protein and affects its biogenesis. J Neurochem 2007,100(6),1505-1514","journal-title":"J Neurochem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0006-291X(05)81503-7","volume":"187","author":"Miura K.","year":"1992","unstructured":"Miura K.; Titani K.; Kurosawa Y.; Kanai Y.; Molecular cloning of nucleobindin, a novel DNA-binding protein that contains both a signal peptide and a leucine zipper structure. Biochem Biophys Res Commun 1992,187(1),375-380","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1021\/acs.biochem.6b00660","volume":"56","author":"Kanuru M.","year":"2017","unstructured":"Kanuru M.; Aradhyam G.K.; Chaperone-like activity of calnuc prevents amyloid aggregation. Biochemistry 2017,56(1),149-159","journal-title":"Biochemistry"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"42880","DOI":"10.1038\/srep42880","volume":"7","author":"Bonito-Oliva A.","year":"2017","unstructured":"Bonito-Oliva A.; Barbash S.; Sakmar T.P.; Graham W.V.; Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization. Sci Rep 2017,7(1),42880","journal-title":"Sci Rep"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00264-010-1076-7","volume":"35","author":"Saad F.A.","year":"2011","unstructured":"Saad F.A.; Hofstaetter J.G.; Proteomic analysis of mineralising osteoblasts identifies novel genes related to bone matrix mineralisation. Int Orthop 2011,35(3),447-451","journal-title":"Int Orthop"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.bone.2004.01.019","volume":"34","author":"Petersson U.","year":"2004","unstructured":"Petersson U.; Somogyi E.; Reinholt F.P.; Karlsson T.; Sugars R.V.; Wendel M.; Nucleobindin is produced by bone cells and secreted into the osteoid, with a potential role as a modulator of matrix maturation. Bone 2004,34(6),949-960","journal-title":"Bone"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nrneurol.2015.170","volume":"11","author":"Malkki H.","year":"2015","unstructured":"Malkki H.; NGF gene therapy activates neurons in the AD patient brain. Nat Rev Neurol 2015,11(10),548","journal-title":"Nat Rev Neurol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nm1239","volume":"11","author":"Tuszynski M.H.","year":"2005","unstructured":"Tuszynski M.H.; Thal L.; Pay M.; A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005,11(5),551-555","journal-title":"Nat Med"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/rej.2005.8.131","volume":"8","author":"Ebert A.D.","year":"2005","unstructured":"Ebert A.D.; Svendsen C.N.; A new tool in the battle against Alzheimer\u2019s disease and aging: Ex vivo gene therapy. Rejuvenation Res 2005,8(3),131-134","journal-title":"Rejuvenation Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/cns.12312","volume":"20","author":"Revilla S.","year":"2014","unstructured":"Revilla S.; Ursulet S.; \u00c1lvarez-L\u00f3pez M.J.; Lenti-GDNF gene therapy protects against Alzheimer\u2019s disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther 2014,20(11),961-972","journal-title":"CNS Neurosci Ther"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1566523220999200817164051","volume":"20","author":"Behl T.","year":"2020","unstructured":"Behl T.; Kaur I.; Kumar A.; Mehta V.; Zengin G.; Arora S.; Gene therapy in the management of parkinson\u2019s disease: Potential of GDNF as a promising therapeutic strategy. Curr Gene Ther 2020,20(3),207-222","journal-title":"Curr Gene Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/brb3.117","volume":"3","author":"B\u00e4ck S.","year":"2013","unstructured":"B\u00e4ck S.; Per\u00e4nen J.; Galli E.; Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson\u2019s disease. Brain Behav 2013,3(2),75-88","journal-title":"Brain Behav"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbr.2015.05.002","volume":"291","author":"Kemppainen S.","year":"2015","unstructured":"Kemppainen S.; Lindholm P.; Galli E.; Cerebral dopamine neurotrophic factor improves long-term memory in APP\/PS1 transgenic mice modeling Alzheimer\u2019s disease as well as in wild-type mice. Behav Brain Res 2015,291,1-11","journal-title":"Behav Brain Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"11550","DOI":"10.3390\/ijms222111550","volume":"22","author":"El-Battari A.","year":"2021","unstructured":"El-Battari A.; Rodriguez L.; Chahinian H.; Gene Therapy Strategy for Alzheimer\u2019s and Parkinson\u2019s diseases aimed at preventing the formation of neurotoxic oligomers in SH-SY5Y Cells. Int J Mol Sci 2021,22(21),11550","journal-title":"Int J Mol Sci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/1566523220999200917114101","volume":"21","author":"Puranik N.","year":"2021","unstructured":"Puranik N.; Yadav D.; Chauhan P.S.; Kwak M.; Jin J.O.; Exploring the role of gene therapy for neurological disorders. Curr Gene Ther 2021,21(1),11-22","journal-title":"Curr Gene Ther"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","volume":"175","author":"Friedmann T.","year":"1972","unstructured":"Friedmann T.; Roblin R.; Gene therapy for human genetic disease? Science 1972,175(4025),949-955","journal-title":"Science"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s13311-018-00694-0","volume":"16","author":"Sudhakar V.","year":"2019","unstructured":"Sudhakar V.; Richardson R.M.; Gene therapy for neurodegenerative diseases. Neurotherapeutics 2019,16(1),166-175","journal-title":"Neurotherapeutics"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1227\/01.NEU.0000064808.27512.CF","volume":"52","author":"Dunn I.F.","year":"2003","unstructured":"Dunn I.F.; Black P.M.; The neurosurgeon as local oncologist: Cellular and molecular neurosurgery in malignant glioma therapy. Neurosurgery 2003,52(6),1411-1424","journal-title":"Neurosurgery"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12035-021-02555-y","volume":"59","author":"Parambi D.G.T.","year":"2022","unstructured":"Parambi D.G.T.; Alharbi K.S.; Kumar R.; Gene therapy approach with an emphasis on growth factors: Theoretical and clinical outcomes in neurodegenerative diseases. Mol Neurobiol 2022,59(1),191-233","journal-title":"Mol Neurobiol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"Gilbert L.A.","year":"2013","unstructured":"Gilbert L.A.; Larson M.H.; Morsut L.; CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013,154(2),442-451","journal-title":"Cell"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"Anzalone A.V.","year":"2019","unstructured":"Anzalone A.V.; Randolph P.B.; Davis J.R.; Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019,576(7785),149-157","journal-title":"Nature"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"Chen P.J.","year":"2021","unstructured":"Chen P.J.; Hussmann J.A.; Yan J.; Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 2021,184(22),5635-5652.e29","journal-title":"Cell"},{"key":"ref=90","first-page":"3","volume":"14","author":"Ridler C.","year":"2018","unstructured":"Ridler C.; Alzheimer disease: CRISPR activation reveals hidden \u03b3-secretase defect in fibroblasts from patients with familial AD. Nat Rev Neurol 2018,14(1),3","journal-title":"Nat Rev Neurol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.3390\/ijms21072329","volume":"21","author":"Peddle C.F.","year":"2020","unstructured":"Peddle C.F.; Fry L.E.; McClements M.E.; MacLaren R.E.; CRISPR interference\u2013potential application in retinal disease. Int J Mol Sci 2020,21(7),2329","journal-title":"Int J Mol Sci"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523223666230419101023","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216044\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523223666230419101023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T04:59:31Z","timestamp":1691557171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216044\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523223666230419101023","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}